Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Alborino, F; Burighel, A; Tiller, FW; van Helden, J; Gabriel, C; Raineri, A; Catapano, R; Stekel, H.
Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity.
Med Microbiol Immunol. 2011; 200(2): 77-83. Doi: 10.1007/s00430-010-0171-0
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz
GABRIEL Christian
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Early detection of hepatitis C virus (HCV) is an important step in preventing progression to cirrhosis and hepatocellular carcinoma. Serologic assays for anti-hepatitis C (anti-HCV) antibody are valuable first-line tests in the screening and diagnosis of HCV infection. The aim of this multicenter study was to compare the Elecsys(®) Anti-HCV assay with alternative CE-marked Anti-HCV antibody assays against a range of samples that included 1,138 blood donors, 3,553 unselected routine daily specimens, and 46 pre-selected seroconversion panels. Specificity of the Elecsys Anti-HCV assay was 99.5% with blood donor samples and 99.4% with routine clinical specimens. These were similar to those obtained with the Prism(®) Anti-HCV, Architect(®) Anti-HCV assay, ADVIA(®) Centaur Anti-HCV assay and Vitros(®) Eci aHCV assays. Seroconversion sensitivity for the Elecsys Anti-HCV assay was similar to that of the Architect Anti-HCV, AxSYM HCV version 3.0, ADVIA Centaur Anti-HCV, and Vitros Eci aHCV assays. In fact, seroconversion testing on 46 commercially available panels showed that the difference in first detecting a positive blood sample was less than one day between assays (not statistically significant). The Elecsys Anti-HCV assay as well as the Architect, Prism, and Vitros Anti-HCV immunoassays revealed a seroconversion sensitivity of 100%, whereas the ADVIA Centaur HCV immunoassay showed a sensitivity of only 97.5% (39/40). Overall, the performance of the Elecsys Anti-HCV assay was similar to the performances of the comparator CE-marked Anti-HCV antibody assays.
Find related publications in this database (using NLM MeSH Indexing)
Automation -
Hepacivirus - immunology
Hepatitis C - diagnosis Hepatitis C - immunology Hepatitis C - virology
Hepatitis C Antibodies - blood
Humans -
Mass Screening - methods
Reagent Kits, Diagnostic -
Sensitivity and Specificity -

Find related publications in this database (Keywords)
Hepatitis C virus
Anti-HCV antibody screening
Elecsys Anti-HCV
Architect Anti-HCV
ADVIA Centaur Anti-HCV
Vitros Eci aHCV
© Med Uni GrazImprint